Note: Where available, the PDF/Word icon below is provided to view the complete and fully formatted document
 Download Current HansardDownload Current Hansard    View Or Save XMLView/Save XML

Previous Fragment    Next Fragment
Thursday, 12 August 2004
Page: 26383


Senator HILL (Minister for Defence) (5:34 PM) —When I answered Senator Ridgeway, perhaps before Senator Allison came into the chamber, basically I said that the US companies want greater transparency in terms of why a product was not listed. We do not see a downside in that. In fact, as I said, it could even be argued that it provided some upside. That was the last question. Before that, I thought Senator Allison was leading me into a more general discussion of the key principles in relation to the pharmaceutical part of the agreement, in which case I was going to draw her attention to the agreed principles as set out in annex 2-C, which states:

The Parties are committed to facilitating high quality health care and continued improvements in public health for their nationals.

And it sets out the principles, one of which is:

... the need to promote timely and affordable access to innovative pharmaceuticals through transparent, expeditious, and accountable procedures ...

But you can read those as well as I can—and presumably have.